<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01539928</url>
  </required_header>
  <id_info>
    <org_study_id>NMA 61 DILUCE</org_study_id>
    <nct_id>NCT01539928</nct_id>
  </id_info>
  <brief_title>Dual PET/CT Imaging in Lung Cancer</brief_title>
  <acronym>DILUCE</acronym>
  <official_title>Dual PET/CT Imaging in Lung Cancer (Danish Title: En og Tre Timers FDG-PET/CT Ved Lungecancer)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare conventional PET/CT scan performed 1 hour after
      injection of the radioactive tracer FDG (PET/CT[1]) with PET/CT performed after 3 hours
      (PET/CT[3]) in a group of patients with biopsy verified lung cancer or high suspicion of lung
      cancer after initial work-up (chest x-ray and CT of thorax/upper abdomen), who are
      potentially operable.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators also want to:

        -  To find the sensitivity, specificity and accuracy in PET/CT 1h and 3 h in the staging of
           lung cancer (N-/M-stage). Our gold standard is pathology, when not possible - follow-up
           (se Gold Standard 6.1.1)

        -  To compare SUVmax with the expression of GLUT1 and G-6-Pase in tumors

        -  To compare the expression of GLUT1 with the activity of G6Pase

        -  To compare SUVmax, RI, tumor/liver ratio, GLUT1 and G-6-Pase with the occurrence of
           relapse within a year after curative surgery
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity, specificity and accuracy</measure>
    <time_frame>After staging or 1 year of follow up</time_frame>
    <description>To find the sensitivity, specificity and accuracy in PET/CT 1h and 3 h in the staging of lung cancer (N-/M-stage). Our gold standard is pathology, when not possible - follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurence of relapse</measure>
    <time_frame>1 year follow up after surgery</time_frame>
    <description>• To compare SUVmax, RI, tumor/liver ratio, GLUT1 and G-6-Pase with the occurrence of relapse within a year after curative surgery</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>lung cancer or high suspicion of lung cancer</arm_group_label>
    <description>After initial work-up (chest x-ray, CT of thorax and upper abdomen, spirometry) found to have surgically resectable lung cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dual FDG-PET/CT</intervention_name>
    <description>Conventional FDG-PET/CT preformed after 1 hour and additional PET/CT 3 hours after injection</description>
    <arm_group_label>lung cancer or high suspicion of lung cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fresh frozen sample of primary lung cancer tumor
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pt. referred to The Department of Pulmonary Medicine, Odense University Hospital or The
        Department of Medicine, Hospital of Southern Denmark, Sønderborg with suspicion of lung
        cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytologic/histologic-verified lung cancer or high suspicion of lung cancer after
             initial work up

          -  Candidate to curative intended surgery after initial work up (usually chest x-ray, CT
             of chest/upper abdomen and if needed spirometry).

        Exclusion Criteria:

          -  Former lung cancer

          -  Contraindications for PET/CT: Pregnancy, recent chemoradiotherapy

          -  Diabetes mellitus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mie H Vilstrup, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mie H Vilstrup, MD, Principal investigor</last_name>
    <phone>+45 2159 3008</phone>
    <email>mie.holm.vilstrup@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Poul Flemming Høilund-Carlsen, MD, DMSc, Professor</last_name>
    <phone>+45 3016 1445</phone>
    <email>pfhc@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pulmonary Medicine</name>
      <address>
        <city>Odense C</city>
        <state>Fünen</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Christian Hansen, MD</last_name>
      <email>niels.christian.hansen@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2012</study_first_submitted>
  <study_first_submitted_qc>February 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2012</study_first_posted>
  <last_update_submitted>June 24, 2013</last_update_submitted>
  <last_update_submitted_qc>June 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Mie Holm Vilstrup</investigator_full_name>
    <investigator_title>Principal investigator, MD</investigator_title>
  </responsible_party>
  <keyword>Dual time PET/CT</keyword>
  <keyword>glucose-6-phosphatase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

